Abstract 232P
Background
An ongoing field of research examines the use of the proteasome genes as prognostic biomarkers in cancer. The cross talk between such machinery and VHL is well rectified, so it is of a great interest to study the prognostic utility of the 20S proteasome gene family in VHL-mutated ccRCC cohort.
Methods
Clinical and transcriptomics data of VHL-mutated ccRCC patients were obtained from the Cancer Genome Atlas Program (TCGA). A total of 11 genes of the 20S proteasome β-subunit (PSMB1-11) were retrieved and tested for their prognostic potential using multivariate Cox logistic regression. The immune suppressive landscape was viewed through the assessment of M2 macrophages (M2M), cancer-associated fibroblasts (CAF), T-regulatory cells (Tregs), and myeloid-derived suppressor cells (MDSC) infiltration using xCell. Correlations with T-cell exhaustion genes were performed additionally.
Results
A total of six genes exhibited significant prognostic indicators, including PSMB1 (HR: 2.113, 95% CI: 1.101-4.056, P = .024), PSMB2 (HR: 2.303, 95% CI: 1.168-4.542, P = .016), PSMB4 (HR: 2.165, 95% CI: 1.075-4.361, P = .031), PSMB6 (HR: 2.956, 95% CI: 1.458-5.998, P = .003), PSMB7 (HR: 2.168, 95% CI: 1.127-4.170, P = .020), and PSMB10 (HR: 2.227, 95% CI: 1.109-4.469, P = .024). Immunosuppressive cells infiltration analysis revealed the following significant correlations (P < .05): PSMB1: MDSC (ρ = 0.316), PSMB2: M2M (ρ = 0.242) and MDSC (ρ = 0.268), PSMB4: M2M (ρ = 0.159) and MDSC (ρ = 0.372), PSMB6: M2M (ρ = 0.247) and MDSC (ρ = 0.412), PSMB7: MDSC (ρ = 0.298), and PSMB10: M2M (ρ = 0.283) and MDSC (ρ = 0.271). No significant correlations were observed in CAF infiltration. Surprisingly, all the markers negatively correlated with Tregs infiltration. The prognostic genes followed a unified pattern of correlation with T-cell exhaustion genes in which positive significant correlations to CTLA4, LAG3, and GZMB were observed. In contrast, all the markers negatively correlated with CD274 (PD-L1) expression.
Conclusions
Several members of the 20S proteasome β-subunit gene family exhibit a prognostic role in VHL-mutated ccRCC and induce an immunosuppressive tumor microenvironment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
551P - Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
Presenter: Andrea Knox
Session: Poster Display
Resources:
Abstract
552P - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Yasushi Goto
Session: Poster Display
Resources:
Abstract
553P - Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong
Presenter: Janet Du
Session: Poster Display
Resources:
Abstract
554P - Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study
Presenter: Kazuhito Miyazaki
Session: Poster Display
Resources:
Abstract
555P - Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong
Presenter: Jason C S Ho
Session: Poster Display
Resources:
Abstract
556P - Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
Presenter: xuezhi Hao
Session: Poster Display
Resources:
Abstract
557P - Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Presenter: Shasha Wang
Session: Poster Display
Resources:
Abstract
558P - Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK+ NSCLC in South Korea
Presenter: Jeong Eun Lee
Session: Poster Display
Resources:
Abstract
559P - Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC
Presenter: Zhaohui Arter
Session: Poster Display
Resources:
Abstract
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract